A phase 2/3 trial evaluates the efficacy and safety of neoadjuvant therapy with gemcitabine-oxaliplatin, lenvatinib, and toripalimab in patients with high-risk intrahepatic cholangiocarcinoma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/neoadjuvant-golp-boosts-event-free-survival-liver-cancer-2026a1000755?src=rss
Author :
Publish date : 2026-03-09 12:53:00
Copyright for syndicated content belongs to the linked Source.